PBAC's latest decision on Chorionic gonadotrophin: Recommended (2017). Considered for Treatment of anovulatory infertility, infertility, combined deficiency of human growth hormone and gonadotrophins, hypogonadism or delayed puberty, and assisted reproductive technology.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Not modelled
no economic evaluation
Submissions
1
first 2017
Submissions
1
2017 → 2017
Eligible population
Patients with anovulatory infertility, infertility associated with hypogonadotrophic hypogonadism or isolated luteinising hormone deficiency, combined deficiency of human growth hormone and gonadotrophins, hypogonadism or delayed puberty (males aged ≥16 years), or undergoing assisted reproductive technology.
Therapy area
Women's health
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Economic model
Cost-minimisation
ICER note
Not modelled — minor submission for new formulation (powder vial) of existing drug with direct substitution and no additional financial impact.